Philip Hei Li Selected Research

Philip Hei Li Research Topics

Disease

9	Hypersensitivity (Allergy) 01/2022 - 06/2017
4	Infections 11/2021 - 03/2017
4	Drug Hypersensitivity (Drug Allergy) 11/2020 - 08/2019
3	Neoplasms (Cancer) 01/2022 - 01/2020
3	Anaphylaxis (Anaphylactic Shock) 01/2022 - 09/2019
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 01/2020
1	Lupus Nephritis 03/2022
1	Proteinuria 03/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Reinfection 01/2022
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2022
1	Epstein-Barr Virus Infections 01/2022
1	Uterine Cervical Dysplasia 01/2022
1	Diabetes Mellitus 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Myocardial Infarction 01/2021
1	Stroke (Strokes) 01/2021
1	Drug-Related Side Effects and Adverse Reactions 11/2020
1	Cicatrix (Scar) 01/2020
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020
1	Urticaria (Hives) 01/2020
1	Uveitis 01/2020
1	Peritonitis 03/2017
1	Hypoalbuminemia 03/2017

Drug/Important Bio-Agent (IBA)

7	Pharmaceutical PreparationsIBA 01/2022 - 03/2017
3	Anti-Bacterial Agents (Antibiotics)IBA 11/2020 - 03/2017
3	beta-LactamsIBA 11/2020 - 08/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 04/2019
2	VaccinesIBA 01/2022 - 06/2017
2	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 03/2021 - 08/2019
2	Penicillins (Penicillin)FDA Link 03/2021 - 01/2020
2	Contrast MediaIBA 10/2020 - 01/2020
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2020 - 01/2020
1	prednylidene (Pred)IBA 03/2022
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 03/2022
1	Prednisolone (Predate)FDA LinkGeneric 03/2022
1	Tacrolimus (Prograf)FDA LinkGeneric 03/2022
1	Calcineurin InhibitorsIBA 03/2022
1	Ustekinumab (CNTO 1275)FDA Link 01/2022
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2022
1	Adalimumab (Humira)FDA Link 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Etanercept (Enbrel)FDA Link 01/2022
1	secukinumabIBA 01/2022
1	Antirheumatic Agents (DMARD)IBA 01/2022
1	Excipients (Suspending Agents)IBA 01/2022
1	Biological ProductsIBA 01/2022
1	Leflunomide (Arava)FDA LinkGeneric 01/2022
1	Inosine Triphosphate (ITP)IBA 01/2022
1	golimumab FDA Link 01/2022
1	MagnesiumIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	Infliximab (Remicade)FDA Link 01/2022
1	GlucocorticoidsIBA 11/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 03/2021
1	omega-Chloroacetophenone (Mace)IBA 01/2021
1	Epinephrine (Adrenaline)FDA LinkGeneric 11/2020
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020
1	beta Lactam AntibioticsIBA 01/2020
1	Carbamazepine (Tegretol)FDA LinkGeneric 01/2020
1	Immunoglobulin E (IgE)IBA 01/2020
1	HLA-B Antigens (HLA-B)IBA 01/2020
1	Allopurinol (Remid)FDA LinkGeneric 01/2020
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020
1	PolylysineIBA 09/2019
1	Ampicillin (Omnipen)FDA LinkGeneric 09/2019
1	Amoxicillin (Wymox)FDA LinkGeneric 09/2019
1	Meropenem (Merrem)FDA LinkGeneric 09/2019
1	Penicillin G (Benzylpenicillin)FDA LinkGeneric 09/2019
1	Carbapenems (Carbapenem Antibiotics)IBA 03/2017

Therapy/Procedure

2	Therapeutics 03/2022 - 01/2020
1	Percutaneous Coronary Intervention 01/2020
1	Catheters 03/2017
1	Peritoneal Dialysis 03/2017